ENT newsroom
United Healthcare Medicare Advantage policy update
Portage, Michigan, USA – October 31, 2025 – Stryker, a global leader in medical technologies, today announced that United Healthcare has removed language deeming ClariFix CPT® 31243 as experimental,investigational, and unproven from their Medicare Advantage policy effective immediately. This update marks a significant advancement in patient access to an evidence-based treatment for chronic rhinitis.
Read MoreCigna Coverage Policy Update for ClariFix® Cryotherapy, Enhancing Patient Access for Chronic Rhinitis Treatment
Portage, Michigan, USA – July 7, 2025 – Stryker, a global leader in medical technologies,today announced that Cigna Healthcare will reclassify ClariFix® (CPT® 31243), removing it from the insurer’s experimental, investigational, and unproven procedures list, effective September 15, 2025. This policy update marks a significant advancement in patient access to an evidence-based treatment for chronic rhinitis.
Read MoreStryker announces creation of new nasal valve collapse ICD-10-CM codes for accurate diagnosis reporting
Portage, Michigan, USA – October 10, 2024 – Stryker, a global leader in medical technologies, announces that the Centers for Disease Control (CDC) and Centers for Medicare and Medicaid Services (CMS) have released new diagnosis codes for nasal valve collapse (NVC), effective October 1, 2024.
Read MoreNew real-world health economic study demonstrates substantial healthcare savings with the LATERA® absorbable nasal implant system
Portage, Michigan, USA – August 23, 2024 – Stryker, a global leader in medical technologies, announced the publication of a new health economic study that has unveiled substantial potential cost savings associated with the LATERA® absorbable nasal implant system. LATERA was compared to traditional surgical repair for the treatment of nasal valve collapse (NVC). The study, which analyzed claims data from thousands of patients, demonstrates that payers could save approximately $2,200 per patient on the date of the procedure by opting for the minimally invasive LATERA approach over surgical intervention.
Read More